Cascadian Therapeutics (NASDAQ: CASC) and Ignyta (NASDAQ:RXDX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.
Earnings and Valuation
This table compares Cascadian Therapeutics and Ignyta’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cascadian Therapeutics||N/A||N/A||-$56.93 million||($1.34)||-7.45|
This table compares Cascadian Therapeutics and Ignyta’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
81.4% of Cascadian Therapeutics shares are owned by institutional investors. Comparatively, 72.3% of Ignyta shares are owned by institutional investors. 1.1% of Cascadian Therapeutics shares are owned by insiders. Comparatively, 13.1% of Ignyta shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a summary of current recommendations for Cascadian Therapeutics and Ignyta, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cascadian Therapeutics currently has a consensus price target of $7.00, suggesting a potential downside of 29.86%. Ignyta has a consensus price target of $26.40, suggesting a potential downside of 2.15%. Given Ignyta’s higher probable upside, analysts plainly believe Ignyta is more favorable than Cascadian Therapeutics.
Risk and Volatility
Cascadian Therapeutics has a beta of 3.79, indicating that its share price is 279% more volatile than the S&P 500. Comparatively, Ignyta has a beta of 184.87, indicating that its share price is 18,387% more volatile than the S&P 500.
Cascadian Therapeutics beats Ignyta on 7 of the 10 factors compared between the two stocks.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.
Ignyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.